Sucampo Pharma Americas Revenue, Growth & Competitor Profile

DBA Sucampo Pharmaceuticals, Inc.

Company Profile & Annual Report for Sucampo Pharma Americas

Access the complete profile.

Sucampo Pharma Americas Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	675 Mcdonnell Boulevard Hazelwood, MO 63042

Sucampo Pharma Americas's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Sucampo Pharma Americas's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Sucampo Pharma Americas is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Sucampo Pharma Americas is a publicly traded company on using the ticker symbol SCMP. Detailed information on company financials and operating reports can be found here: : SCMP

Sucampo Pharma Americas Annual Revenue and Growth Rate

Sucampo Pharma Americas	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Sucampo Pharma Americas's revenues are gauged from an analysis of company filings.

Trademark Applications

Trademark applications show the products and services that Sucampo Pharma Americas is developing and marketing. Sucampo Pharma Americas doesn't have any recent trademark applications, indicating Sucampo Pharma Americas is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
AZURIL Pharmaceutical preparations for the treatment of gastrointestinal diseases	03/13/2009
ZALM Pharmaceutical preparations for the treatment of gastrointestinal diseases	03/13/2009
ARROCO Pharmaceutical preparations for the treatment of gastrointestinal diseases	03/13/2009

See all trademarks and details in the Full Report.

Market Share of Sucampo Pharma Americas's Largest Competitors

A competitive analysis shows these companies are in the same general field as Sucampo Pharma Americas, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Sucampo Pharma Americas. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
MEH	Hazelwood, MO	100
MALLINCKRODT ENTERPRISES	Hazelwood, MO	87
MALLINCKRODT HOSPITAL PRODUCTS	Hazelwood, MO	4
LEE BIOSOLUTIONS	Maryland Heights, MO	3
EBM MEDICAL	Chesterfield, MO	2
SENTIO BIOSCIENCES	Maryland Heights, MO	1

Other Companies at 675 Mcdonnell Boulevard, Hazelwood MO

Company	Headquarters	Revenue ($ MM)
MEH	Hazelwood, MO	100
MALLINCKRODT ENTERPRISES	Hazelwood, MO	87
MALLINCKRODT HOSPITAL PRODUCTS	Hazelwood, MO	4
CNS THERAPEUTICS	Hazelwood, MO	0

Future Competition: Sucampo Pharma Americas's Fastest Growing Competitors

These companies are in the same general field as Sucampo Pharma Americas and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)